Paris-based venture capital firm, Sofinnova Partners, has closed its Sofinnova Capital VIII fund with €300 million ($324 million) that will be dedicated toward adding 15 to 20 more biotech companies to its portfolio, two thirds of which will reportedly be in Europe, the rest in North America.
Back in 2012, the firm raised €240m, and with this new fund it brings the current amount under management at Sofinnova Partners to €1.5 billion ($1.6 billion). The company’s focus will remain in the biopharmaceutical and medical device sectors.
“Our experienced team, stable strategy and exit track record resonated well with investors, hence the success and speed of our fundraising for this fund,” Antoine Papiernik, Managing Partner at Sofinnova Partners, said in a company statement. “Over the last three years, we completed 10 remarkable exits in the portfolio for a total enterprise value of almost 3 billion euros.”
With the Rise of AI, What IP Disputes in Healthcare Are Likely to Emerge?
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
International investors, the majority from Europe, including France, Italy, Sweden, Norway, Switzerland, Belgium and Luxembourg, as well as from leading North American investors in the US and Canada contributed to the fund. Money primarily came from pension funds, funds of funds, family offices and insurance companies.
“We are honored by our investors’ support, which will allow us to transform entrepreneurs’ vision into successful businesses, and help bring life saving innovations to the medical community and patients,” said Rafaèle Tordjman, Managing Partner at Sofinnova Partners.
Photo: Flickr user Photo from Flickr user Images Money
